‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.
Therapy Area
MHRA warns women using weight loss jabs must use effective contraception
Ascletis’s daily acne tablet set for China review after Phase III win
Redwire gains Aspera contract for space-based cancer research
Agenus and Zydus sign agreements for botensilimab and balstilimab
Roche extends SMA market lead with Evrysdi tablet approval in Europe
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia
